Page 13 - மகில் பல்கலைக்கழகம் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Dec 21, 2020 Collaboration Strengthens Peijia s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife s Technology SUZHOU, China and PARIS, Dec. 20, 2020 /PRNewswire/ Peijia Medical Ltd (HK Stock Code: 09996) and HighLife SAS, a Paris-based medical device company, focused on the development of a unique transeptal mitral valve replacement ( TMVR ) system to treat patients suffering from mitral regurgitation, announced that they have entered into a license agreement pursuant to which HighLife has granted to Peijia an exclusive license regarding certain proprietary TMVR products currently in development by the Licensor. Under the Agreement, Peijia is entitled to, among other things, manufacture, develop, and commercialize the products in the greater China region, and HighLife is in return entitled to receive an upfront fee and subsequent milestone payments.

France generalHong kongYi zhangNicolo piazzaGlobal expansion of highlife technologyPrnewswire peijia medical ltd hk stock codePeijia medicalMcgill university health centreCorevalve incCollaboration strengthens peijiaLargely untapped marketSupports global expansionMedical ltdMcgill university healthKey opinion leaderPrincipal investigator